0001628280-24-042941.txt : 20241016 0001628280-24-042941.hdr.sgml : 20241016 20241016165443 ACCESSION NUMBER: 0001628280-24-042941 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241015 FILED AS OF DATE: 20241016 DATE AS OF CHANGE: 20241016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ragan Paula CENTRAL INDEX KEY: 0001769914 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 241375191 MAIL ADDRESS: STREET 1: C/O X4 PHARMACEUTICALS, INC. STREET 2: 955 MASSACHUSETTS AVE., 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 wk-form4_1729112077.xml FORM 4 X0508 4 2024-10-15 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001769914 Ragan Paula C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET, 4TH FLOOR BOSTON MA 02134 1 1 0 0 President and CEO 0 Common Stock 2024-10-15 4 S 0 31897 0.562 D 1025816 D These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5424 to $0.5806, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Adam S. Mostafa, attorney-in-fact 2024-10-16